WO2008130814A3 - Use of an mmp28 inhibitor for increasing myelination - Google Patents

Use of an mmp28 inhibitor for increasing myelination Download PDF

Info

Publication number
WO2008130814A3
WO2008130814A3 PCT/US2008/059335 US2008059335W WO2008130814A3 WO 2008130814 A3 WO2008130814 A3 WO 2008130814A3 US 2008059335 W US2008059335 W US 2008059335W WO 2008130814 A3 WO2008130814 A3 WO 2008130814A3
Authority
WO
WIPO (PCT)
Prior art keywords
mmp28
inhibitor
myelination
mmp28 inhibitor
increasing myelination
Prior art date
Application number
PCT/US2008/059335
Other languages
French (fr)
Other versions
WO2008130814A2 (en
Inventor
Sean Richard Werner
Original Assignee
Lilly Co Eli
Sean Richard Werner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Sean Richard Werner filed Critical Lilly Co Eli
Priority to CA002682282A priority Critical patent/CA2682282A1/en
Priority to EP08745063A priority patent/EP2142645A2/en
Priority to AU2008242375A priority patent/AU2008242375B2/en
Priority to JP2010504156A priority patent/JP2010524949A/en
Publication of WO2008130814A2 publication Critical patent/WO2008130814A2/en
Publication of WO2008130814A3 publication Critical patent/WO2008130814A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of an MMP28 inhibitor, e.g., an anti-MMP28 antibody, to increase myelination. The methods of the present invention are accomplished by administering an MMP28 inhibitor to a subject having a demyelination or insufficient myelination disease, disorder or condition.
PCT/US2008/059335 2007-04-18 2008-04-04 Use of an mmp28 inhibitor for increasing myelination WO2008130814A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002682282A CA2682282A1 (en) 2007-04-18 2008-04-04 Use of an mmp28 inhibitor for increasing myelination
EP08745063A EP2142645A2 (en) 2007-04-18 2008-04-04 Use of an mmp28 inhibitor for increasing myelination
AU2008242375A AU2008242375B2 (en) 2007-04-18 2008-04-04 Use of an MMP28 inhibitor for increasing myelination
JP2010504156A JP2010524949A (en) 2007-04-18 2008-04-04 Use of an MMP28 inhibitor to increase myelin formation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91243307P 2007-04-18 2007-04-18
US60/912,433 2007-04-18
US97657007P 2007-10-01 2007-10-01
US60/976,570 2007-10-01

Publications (2)

Publication Number Publication Date
WO2008130814A2 WO2008130814A2 (en) 2008-10-30
WO2008130814A3 true WO2008130814A3 (en) 2009-03-19

Family

ID=39876137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/059335 WO2008130814A2 (en) 2007-04-18 2008-04-04 Use of an mmp28 inhibitor for increasing myelination

Country Status (5)

Country Link
EP (1) EP2142645A2 (en)
JP (1) JP2010524949A (en)
AU (1) AU2008242375B2 (en)
CA (1) CA2682282A1 (en)
WO (1) WO2008130814A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532265A (en) * 1994-11-30 1996-07-02 The Board Of Trustees Of The Leland Stanford Junior University Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors
EP0733369A1 (en) * 1995-03-23 1996-09-25 Stichting REGA V.Z.W. Protease inhibitors, a DNA construct for the expression of a protease and a process for measuring proteases and/or protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532265A (en) * 1994-11-30 1996-07-02 The Board Of Trustees Of The Leland Stanford Junior University Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors
EP0733369A1 (en) * 1995-03-23 1996-09-25 Stichting REGA V.Z.W. Protease inhibitors, a DNA construct for the expression of a protease and a process for measuring proteases and/or protease inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GIJBELS K ET AL: "REVERSAL OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS WITH A HYDROXAMATE INHIBITOR OF MATRIX METALLOPROTEASES", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 94, no. 6, 1 December 1994 (1994-12-01), pages 2177 - 2182, XP000574655, ISSN: 0021-9738 *
MARCHENKO G N ET AL: "MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors", GENE, ELSEVIER, AMSTERDAM, NL, vol. 265, no. 1-2, 7 March 2001 (2001-03-07), pages 87 - 93, XP004230726, ISSN: 0378-1119 *
See also references of EP2142645A2 *
VOON WEE YONG ET AL: "MATRIX METALLOPROTEINASES AND DISEASES OF THE CNS", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 2, 1 January 1998 (1998-01-01), pages 75 - 80, XP000942162, ISSN: 0166-2236 *
WERNER SEAN R ET AL: "MMP-28 as a regulator of myelination", BMC NEUROSCIENCE, vol. 9, September 2008 (2008-09-01), pages Article No.: 83, XP002509977, ISSN: 1471-2202 *
WERNER SEAN R ET AL: "Neural MMP-28 expression precedes myelination during development and peripheral nerve repair", DEVELOPMENTAL DYNAMICS, vol. 236, no. 10, October 2007 (2007-10-01), pages 2852 - 2864, XP002509976, ISSN: 1058-8388 *

Also Published As

Publication number Publication date
CA2682282A1 (en) 2008-10-30
AU2008242375B2 (en) 2011-04-14
AU2008242375A1 (en) 2008-10-30
WO2008130814A2 (en) 2008-10-30
JP2010524949A (en) 2010-07-22
EP2142645A2 (en) 2010-01-13

Similar Documents

Publication Publication Date Title
CY1122278T1 (en) ANTI IL-36R ANTIBODIES
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2009077857A3 (en) Trail variants for treating cancer
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
UA111818C2 (en) ANTIBODY AGAINST CSF-1R
WO2009137378A3 (en) Sequential administration of chemotherapeutic agents for treatment of cancer
WO2012149389A3 (en) Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2008082613A3 (en) Factor ix moiety-polymer conjugates having a releasable linkage
MA34641B1 (en) ANTI-IL-23 ANTIBODIES
WO2010064012A3 (en) Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 )
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
CL2008000322A1 (en) PROCESS FOR THE PREPARATION OF A COMPOUND DERIVED FROM 2-TIAZOL-2-IL-QUINOLINA; INTERMEDIARY COMPOUNDS; AND PREPARATION PROCESS OF SUCH INTERMEDIATE COMPOUNDS.
BR112012017051A2 (en) method to decrease immunogenicity
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
EA200900767A1 (en) ANTAGONISTIC ANTIBODIES AGAINST EPHB3
MX2009008660A (en) Method for the preparation of therapeutically valuable triphenylbutene derivatives.
SG154441A1 (en) Treatment of demyelinating disorders
WO2010014258A3 (en) Conjugates having a releasable linkage
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2009000777A3 (en) Imaging diagnostics by combining contrast agents
DE112007003101A5 (en) Telemedicine system, especially for chronic diseases
WO2011133226A3 (en) Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
WO2009124733A8 (en) Substituted sulfonamide derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2008242375

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008242375

Country of ref document: AU

Date of ref document: 20080404

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2682282

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010504156

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008745063

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08745063

Country of ref document: EP

Kind code of ref document: A2